Multiple Myeloma and EasyM Resource Centre.
Featured
Measurable Residual Disease and Decision-Making in Multiple Myeloma
wtang@rapidnovor.com2025-02-28T09:22:26-05:00August 3rd, 2024|Case Studies|
Publications, Posters & Case Studies
wtang@rapidnovor.com2025-02-19T15:32:29-05:00
Novel Assay for Quantification of Free Light Chain (FLC) Dimers in Serum of Patients with Plasma Cell Dyscrasias
wtang@rapidnovor.com2025-02-19T15:32:29-05:00December 17th, 2023|Poster|
wtang@rapidnovor.com2025-02-19T14:30:19-05:00
Measurable Residual Disease Status By Clonotypic Mass Spectrometry with EasyM Assay Predicts Outcomes Following AHCT in Multiple Myeloma
wtang@rapidnovor.com2025-02-19T14:30:19-05:00December 15th, 2023|Poster|
wtang@rapidnovor.com2025-02-19T14:49:14-05:00
Clonotypic Mass Spectrometry with EasyM Assay for Detection of Measurable Residual Disease in Multiple Myeloma
wtang@rapidnovor.com2025-02-19T14:49:14-05:00December 17th, 2022|Poster|